amanuensis wrote: ↑Fri Jun 11, 2021 7:14 am
I note that the most recent Yellow-Card update shows an increase in menstruation related side-effects of 50% (AZ) and 30% (Pfizer) -- for a single week.
It really is a rubbish system -- entries are far more closely correlated with the enthusiasm to report at the time, over the actual incidence rate of the side effect.
Thats an unfortunate side effect with these systems. They are basically voluntary so the quality of the case history entries tends to be all over the place. But there again most raw data from heterogeneous clinical sources is like that.
But at least based on the experience with VAERS over the decades very useful information can be extracted and deduced using standard data normalization and statistical analysis techniques. By extracting standardized record data and then using the standard data analysis procedures to remove outliers, noise and fix mistakes you at least have a group data set which you can start to compare with the general population data sets. Which is your control group.
Based on analysis done with other vaccines in the VAERS system the types of problems seen with the SARs CoV 2 vaccines are mostly not that different . At least for initial adverse response. What is different is the magnitude of the adverse effects. I have been using the Influenza A/B vaccines VAERS data as my informal control and SARs CoV 2 vaccines are about two orders of magnitude less safe than Influenza A/B vaccines.
Which given that the > 70 risk/benefit profile is about the same and < 70 much higher than with influenza the SARs vaccines fail all traditional metrics for general use of a vaccine. The 5/10 year risk of mortality from SARs CoV 2 is not at least two orders of magnitude greater than for Influenza.
Now what the magnitude of the early VAERS adverse effects entries does look like is the data from early clinical trials of past vaccines candidates which eventually fail to get approval. Because the high rate of adverse effects does not satisfy the health risk / benefit equation. The ultimate decider in all previous approved vaccines for general use.